Diplomat Pharmacy is part of the healthcare sector and is in the drug manufacturers industry. The company CEO is Brian T. Griffin. Diplomat Pharmacy Inc is a provider of pharmaceutical drugs in the United States. It generates its revenue through the sale of prescriptions drugs for serious diseases such as hepatitis and multiple sclerosis.
Previous Intraday Trading Performance:
The DPLO stock showed a previous change of -0.57% with an open at 15.75 and a close of 15.72. It reached an intraday high of 16.00 and a low of 15.45.
The stock has a market cap of $1.2b with 74.5m shares outstanding, of which the float is 72.9m shares. Trading volume reached 804,475 shares compared to its average volume of 1,158,474 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.
Historical Trading Performance:
Over the last five trading days, Diplomat Pharmacy shares returned 0.77% and in the past 30 trading days it returned -24.71%. Over three months, it changed -22.83%. In one year it has changed -13.72% and within that year its 52-week high was 28.74 and its 52-week low was 13.31. DPLO stock is 18.11% above its 52 Week Low.
Our calculations show a 200 day moving average of 21.27 and a 50 day moving average of 18.13. Currently DPLO stock is trading -26.09% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 0.22 that ended on 31st of December 2017, which according to the previous close, that is a PE of 71.45. Based on 9 analyst estimates, the consensus EPS for the next quarter is 0.22. The TTM EPS is 0.80, which comes to a TTM PE of 19.65.
The following are the last four quarter reported earnings per share:
09-30-2018: 0.22 (estimated)
Base on our calculations, the intrinsic value per share is 32.32, which means it is possibly undervalued and has a margin of safety of 51.36%
Indicators to Watch:
Based on the latest filings, there is 142.90% of institutional ownership. Short-interest is 9,407,689, which is 12.63% of shares outstanding. The short-interest ratio or days-to-cover ratio is 8.05. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.
The current calculated beta is 0.87
SeekingAlpha: Depomed beats by $0.03, misses on revenue
Based on last reported financials, the company’s return on equity is 0.33%, return on assets is 0.16%, profit margin is 0.04%, price-to-sales is 0.22 and price-to-book is 1.53.
All scores are out of six:
3 :Valuation Score
1 :Past Performance Score
2 :Financial Strength Score
3 :Future Growth Score
0 :Dividend Score
2 :Overall Score